This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Acorda Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Acorda Therapeutics es Ron Cohen , nombrado en Jan 1995, tiene una permanencia de 28.67 años. compensación anual total es $984.15K, compuesta por 63.5% salario y 36.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.6% de las acciones de la empresa, por valor de €85.15K. La antigüedad media del equipo directivo y de la junta directiva es de 5.6 años y 25.7 años, respectivamente.

Información clave

Ron Cohen

Chief Executive Officer (CEO)

US$984.2k

Compensación total

Porcentaje del salario del CEO	63.5%
Permanencia del CEO	28.7yrs
Participación del CEO	0.6%
Permanencia media de la dirección	5.6yrs
Promedio de permanencia en la Junta Directiva	25.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ron Cohen en comparación con los beneficios de Acorda Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$58m
Dec 31 2022	US$984k	US$625k	-US$66m
Sep 30 2022	n/a	n/a	-US$106m
Jun 30 2022	n/a	n/a	-US$119m
Mar 31 2022	n/a	n/a	-US$95m
Dec 31 2021	US$2m	US$743k	-US$104m
Sep 30 2021	n/a	n/a	-US$166m
Jun 30 2021	n/a	n/a	-US$132m
Mar 31 2021	n/a	n/a	-US$127m
Dec 31 2020	US$2m	US$796k	-US$100m
Sep 30 2020	n/a	n/a	US$49m
Jun 30 2020	n/a	n/a	-US$222m
Mar 31 2020	n/a	n/a	-US$232m
Dec 31 2019	US$2m	US$796k	-US$273m
Sep 30 2019	n/a	n/a	-US$329m
Jun 30 2019	n/a	n/a	-US$79m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$2m	US$796k	US$34m
Sep 30 2018	n/a	n/a	-US$147m
Jun 30 2018	n/a	n/a	-US$158m
Mar 31 2018	n/a	n/a	-US$213m
Dec 31 2017	US$2m	US$792k	-US$223m
Sep 30 2017	n/a	n/a	-US$55m
Jun 30 2017	n/a	n/a	-US$43m
Mar 31 2017	n/a	n/a	-US$53m
Dec 31 2016	US$3m	US$773k	-US$35m

Compensación vs. Mercado: La compensación total de Ron($USD984.15K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD471.14K).

Compensación vs. Ingresos: La compensación de Ron ha sido consistente con los resultados de la empresa en el último año.

CEO

Ron Cohen (67 yo)

28.7yrs

Permanencia

US$984,150

Compensación

Dr. Ron Cohen, M.D., has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer and President since 1995. Dr. Cohen served as Principal in the startup of Advanced...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ron Cohen	Founder	28.7yrs	US$984.15k	0.60% € 85.2k
Michael Gesser	Chief Financial Officer	1.8yrs	US$459.15k	0% € 0
Kerry Clem	Chief Commercial Officer	2yrs	US$592.23k	0.041% € 5.7k
Robert Morales	Interim Principal Accounting Officer	2.5yrs	sin datos	sin datos
Felicia Vonella	Vice President of Investor Relations	no data	sin datos	sin datos
Neil Belloff	General Counsel & Corporate Secretary	1.8yrs	sin datos	0% € 0
Tierney Saccavino	Executive Vice President of Corporate Communications	8.7yrs	sin datos	sin datos
Denise Duca	Executive Vice President of Human Resources	8.7yrs	sin datos	sin datos
Andrew Mayer	Senior Vice President	no data	sin datos	sin datos
Sofia Ali	Senior VP of Operations & Strategic Planning	no data	sin datos	sin datos
Susan Way	Senior VP of Drug Development & Regulatory Affairs	no data	sin datos	sin datos
Wise Young	Special Scientific Advisor	no data	US$10.00k	sin datos

5.6yrs

Permanencia media

61.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CDG es experimentado (5.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ron Cohen	Founder	28.7yrs	US$984.15k	0.60% € 85.2k
Carl Cotman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Sandra Panem	Independent Director	25.7yrs	US$72.64k	0.0019% € 272.6
Mark Tuszynski	Member of Scientific Advisory Board	no data	sin datos	sin datos
Melitta Schachner	Member of Scientific Advisory Board	no data	sin datos	sin datos
Patrick Tresco	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stephen Waxman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Mary Bunge	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Fawcett	Member of Scientific Advisory Board	no data	sin datos	sin datos
Michael Beattie	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jerry Silver	Member of Scientific Advisory Board	no data	sin datos	sin datos
John Kelley	Independent Non-Executive Chairman	14.8yrs	US$127.49k	0% € 0

25.7yrs

Permanencia media

72.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de CDG son experimentados ( 25.7 años antigüedad media).

This company listing is no longer active

Acorda Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Insufficient new directors

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Acorda Therapeutics Announces Executive Changes

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Motion for Joint Administration Filed by Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Revenue beats expectations

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.

New 90-day high: €5.42

Third quarter 2020 earnings released: EPS US$0.15

Revenue beats expectations

New 90-day high: €0.89

Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, Inc

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index

New 90-day low - €0.40

New 90-day low - €0.50

First half earnings released

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Value Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad